Cristina Solé Marce I am a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute. Previously, I held a postdoctoral research position in the same unit, and during my PhD, I conducted research at the University of Durham (Durham, UK), Anacor Pharmaceuticals (California, USA), and Rovira i Virgili University (Tarragona, Catalonia). I hold a dual degree in Chemistry and Biochemistry, and during these studies, I also conducted research at the University of Reading (Reading, UK) and the University of the Balearic Islands (Mallorca, Spain). My research career has focused on autoimmune diseases, particularly on the pathogenesis of lupus and antiphospholipid syndrome, as well as the synthesis and mechanisms of action of biological drugs. Instituciones de las que forman parte Investigador/a principal Reumatología Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Cristina Solé Marce LinkedIn Twitter Orcid Email Instituciones de las que forman parte Investigador/a principal Reumatología Vall Hebron Institut de Recerca I am a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute. Previously, I held a postdoctoral research position in the same unit, and during my PhD, I conducted research at the University of Durham (Durham, UK), Anacor Pharmaceuticals (California, USA), and Rovira i Virgili University (Tarragona, Catalonia). I hold a dual degree in Chemistry and Biochemistry, and during these studies, I also conducted research at the University of Reading (Reading, UK) and the University of the Balearic Islands (Mallorca, Spain). My research career has focused on autoimmune diseases, particularly on the pathogenesis of lupus and antiphospholipid syndrome, as well as the synthesis and mechanisms of action of biological drugs.
Since 2021, I am Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute (VHIR). Previously, I spent six years as a postdoctoral researcher in the same unit. Since then, our focus has been on research aimed at improving patients' lives, whether through the identification of new biomarkers that inform us about their condition without the need for invasive techniques, or through the discovery of the effects of new drugs and/or the molecular pathways involved in the development of different clinical manifestations. In this regard, we have already published several papers in internationally recognized journals and have been invited to prestigious conferences (ACR, EULAR, etc.). Before joining VHIR, I graduated with dual degrees in Chemistry and Biochemistry from Rovira i Virgili University, where I achieved the highest academic record in both programs. I then began my PhD, focusing on the enantioselective synthesis of drugs, while simultaneously completing a master’s degree in "Synthesis and Catalysis" at Rovira i Virgili University. I have completed various research stays at national, European, and international levels. Specifically, I worked at the University of the Balearic Islands with Dr. Palou's team, researching the regulation of metabolism via ghrelin/leptin. I then conducted research at Reading University with Dr. Katja Strohfeldt, synthesizing anticancer drugs based on germanium. Additionally, I worked at Durham University with Dr. Andy Whiting, exploring new enantio- and diastereo-selective pathways for drug synthesis. Finally, before joining my current team, I worked at Anacor Pharmaceuticals in Palo Alto (California, USA), both in the chemical synthesis and biological departments.
Proyectos Teràpia gènica amb miRNAs d'interferència com a nova alternativa de tractament al lupus eritematós discoide (LED) IP: Cristina Solé Marce Colaboradores: - Entidad financiadora: Institut d'Estudis Catalans (IEC) Financiación: 6000 Referencia: IEC/PREMI/2022/SOLE Duración: 01/04/2023 - 31/12/2024 Novel therapeutic topical approach for discoid lupus cutaneous (DLE) treatment IP: Cristina Solé Marce Colaboradores: Berta Ferrer Fábrega, Gloria Aparicio Español Entidad financiadora: Instituto de Salud Carlos III Financiación: 99099 Referencia: PI21/01869 Duración: 01/01/2022 - 31/12/2025 Las células T del receotir del autoantígeno quimérico (CAAR-Tcell) como nueva terapia dirigida para la nefritis lúpica. IP: Josefina Cortes Hernandez Colaboradores: José Ordi Ros, Cristina Solé Marce Entidad financiadora: Instituto de Salud Carlos III Financiación: 122815 Referencia: PI18/01917 Duración: 01/01/2019 - 30/06/2023 Investigación del mecanismo de acción de la Talidomida en el Lupus Discoide para el desarrollo de nuevas terapias IP: Josefina Cortes Hernandez Colaboradores: Jordi Mollet Sánchez, Cristina Solé Marce Entidad financiadora: Instituto de Salud Carlos III Financiación: 104665 Referencia: PI15/02145 Duración: 01/01/2016 - 31/12/2019 Paginación Página actual 1 Página 2 Siguiente página › Última página »
